December 2nd 2024
If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Immature skin poses problems for premature infants, caregivers
February 18th 2005Advances in biologic and clinical research have contributed to improved understanding of the problems associated with immature skin in premature infants, Lawrence F. Eichenfield, M.D., said yesterday at a presentation on "Neonatal Skin and Complications."
Shaking up traditional thinking about dermatologic therapies
February 11th 2005As a dermatologist for 27 years, Norman Levine, M.D., professor of dermatology, University of Arizona College of Medicine, Tucson, and editorial advisor to Dermatology Times, has gathered new insights from clinical experience, reference books, professional meetings and reviews of treatment modalities.
Old therapy offers new hope for skin disease
February 1st 2005Everything old is new again could be the theme of a promising new therapy for sufferers of immune-mediated skin disease — CellCept?. P. R?gine Mydlarski, M.D., F.R.C.P.C., assistant professor at the University of Calgary, says the reformulation of medication that has been around for nearly a century is an up-and-coming treatment for skin conditions in the hands of the dermatologist.
AD treatments exhibit long-term relief for other inflammatory skin conditions
February 1st 2005The efficacy and remarkable safety profile of two drugs, tacrolimus (Protopic?, Fujisawa Healthcare) and pimecrolimus (Elidel?, Novartis), have revolutionized the treatment of atopic dermatitis (AD) and appear to have promise for a variety of other inflammatory skin conditions that require long-term therapy, according to Alan Fleischer, M.D., professor and chair of dermatology at Wake Forest University School of Medicine.
AD treatments exhibit long-term relief for other inflammatory skin conditions
February 1st 2005The efficacy and remarkable safety profile of two drugs, tacrolimus (Protopic?, Fujisawa Healthcare) and pimecrolimus (Elidel?, Novartis), have revolutionized the treatment of atopic dermatitis (AD) and appear to have promise for a variety of other inflammatory skin conditions that require long-term therapy, according to Alan Fleischer, M.D., professor and chair of dermatology at Wake Forest University School of Medicine.
Lipo innovations: Female breast reduction, 'plasty' alternatives expand
February 1st 2005New York — Interest in tumescent liposuction has expanded to a variety of new indications, including postmenopausal "lumpy" back fat deposits and as an alternative to more invasive procedures such as abdominoplasty and surgical mammoplasty, according to Naomi Lawrence, M.D.
Argentine dermatologists target psoriasis, leprosy, skin cancer
February 1st 2005Buenos Aires — "Controle sus lunares por una piel sana" (control your moles for a healthy skin) is a message that people throughout Argentina heard repeatedly last November, thanks to the efforts of Rebeca Rubinson, M.D., and her colleagues at the Sociedad Argentina de Dermatologia (SAD) here. Dr. Rubinson is a pediatric dermatologist affiliated with Hospital Abel Zubizarreta in Buenos Aires and the coordinator of the 2004 campaign on recognition and prevention of skin cancer.
Strive to match 'expectation/performance'
February 1st 2005Kissimmee, Fla. — In dermatology practices today, two basic types of procedures exist: "desire-based" cosmetic procedures and "disease-based" procedures, such as the removal of a skin cancer. Traditionally in medicine, physicians have employed a set of relatively objective criteria to define an acceptable outcome in the second type of procedure. It is the first category, elective and cosmetic procedures, where the physician must satisfy another, more subjective, set of criteria — one that is frequently the cause of disappointment, remorse, dissatisfaction, anger and, all too often, malpractice litigation.
Stepwise treatment approach yields results with atopic dermatitis
February 1st 2005Las Vegas — With the increased efficacy of topical immune modulators in the treatment of atopic dermatitis, Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology and clinical professor of pediatrics and dermatology at the Children'sHospital in San Diego and University of California, San Diego, has established a step approach to the treatment of atopic dermatitis.
Old therapy offers new hope for skin disease
February 1st 2005Everything old is new again could be the theme of a promising new therapy for sufferers of immune-mediated skin disease — CellCept?. P. R?gine Mydlarski, M.D., F.R.C.P.C., assistant professor at the University of Calgary, says the reformulation of medication that has been around for nearly a century is an up-and-coming treatment for skin conditions in the hands of the dermatologist.